Monographie - Caspofungin acetate

Viimeisin päivitys :
18/04/2024

Caspofungin acetate

Kemiallinen rakenne

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Afundas	Turkki
Cagin	Marokko
Cancidas	Argentiina, Australia, Belgia, Brasilia, Chile, Ecuador, Intia, Iran, Irlanti, Islanti, Iso-Britannia, Italia, Japani, Kanada, Kolumbia, Luxemburg, Malesia, Marokko, Meksiko, New Zealand, Norja, Portugali, Ranska, Romania, Ruotsi, Saksa, Saudi-Arabia, Suomi, Sveitsi, Tanska, Turkki, Unkari, Yhdistyneet arabiemiirikunnat, Yhdysvallat
Casfucid	Chile, Ecuador, Marokko
Casfung	Ecuador, Intia
Caspodyan	Chile
Caspofungin	Australia, Hollanti, Irlanti, Iso-Britannia, Italia, Itävalta, Japani, Kreikka, Luxemburg, Norja, Puola, Saksa, Suomi, Sveitsi, Tanska, Unkari, Yhdysvallat
Caspofungina	Brasilia, Chile, Ecuador, Espanja
Caspogin	Intia
Caspopharm	Marokko
Casporan	Intia
Caspovitae	Chile, Marokko
Driken	Marokko
Fentex	Chile
Fhanigun	Meksiko
Fungidas	Turkki
Monmix	Meksiko
Sanicid	Chile
Suvepur	Chile, Meksiko
Ucaspo	Ecuador

Viitteet : Caspofungin acetate

	Tyyppi	Julkaisu
1519	Laboratorio	Caspofungine (Cancidas®) - Summary of Product Characteristics Merck Sharp Dohme 2015
2017	Lehti	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2233	Lehti	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Lehti	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Lehti	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Lehti	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012	Lehti	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3140	Lehti	Tsiouris M, Ulmer M, Yurcho J F, Hooper K L, Gui M. Stability and Compatibility of Reconstituted Caspofungin in Select Elastomeric Infusion Device. Int J Pharm Compound 2010 ; 14, 5 : 436-439.
3216	Lehti	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Lehti	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Lehti	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408	Lehti	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3728	Lehti	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	Lehti	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Lehti	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3827	Ilmoitus	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Ilmoitus	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Ilmoitus	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	Lehti	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	Lehti	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055	Lehti	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4067	Lehti	Pinder N, Pelzl L.H; Walther G, Backhaus J, Kurzai O, Hoppe-Ticky T. Caspofungin infusion solutions (50 mg/mL): chemical stability and antifungal activity against Candida spp. Pharmazie 2017 ;72:197-199
4145	Lehti	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Lehti	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4380	Laboratorio	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4528	Lehti	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Lehti	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratorio	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4655	Lehti	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33

Mentions Légales